pharmaphorum57m
BioNTech buys Biotheus and its Keytruda rival for $950m
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
Sharecast4m
BioNTech to acquire China's Biotheus in $800m deal
including antibody-drug conjugates from its existing portfolio. It said it saw BNT327’s dual-target approach as a significant ...
BioSpace43m
Kezar’s Autoimmune Drug Hit With Second FDA Clinical Hold in as Many Months
Kezar Life Sciences can’t catch a break this fall with its autoimmune candidate zetomipzomib. Just over a month after the FDA ...